Evidence map›Paper›PMID 31527467›Full record

ArticleCancers2019

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.

Isabella Faraoni, Maria Irno Consalvo, Francesca Aloisio, Emiliano Fabiani, Manuela Giansanti, Francesca Di Cristino, Giulia Falconi, Lucio Tentori, Ambra Di Veroli, Paola Curzi and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Isabella FaraoniPharmacology Section, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy. faraoni@med.uniroma2.it.
Maria Irno ConsalvoHematology Section, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Francesca AloisioPharmacology Section, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Emiliano FabianiHematology Section, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6209-8934
Manuela GiansantiPharmacology Section, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Francesca Di CristinoPharmacology Section, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Giulia FalconiHematology Section, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7699-1427
Lucio TentoriPharmacology Section, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-7691-527X
Ambra Di VeroliHematology Section, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Paola CurziHematology Unit, Tor Vergata Hospital, 00133 Rome, Italy.
Luca MaurilloHematology Unit, Tor Vergata Hospital, 00133 Rome, Italy.
Pasquale NiscolaHematology Unit, "S. Eugenio" Hospital, 00144 Rome, Italy.
Francesco Lo-CocoHematology Section, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Grazia GrazianiPharmacology Section, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-0221-768X
Maria Teresa VosoHematology Section, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy. voso@med.uniroma2.it.ORCID 0000-0002-6164-4761
University of Rome Tor Vergata · ITSt. Eugenio Hospital · IT

Funding

Associazione Italiana per la Ricerca sul Cancro IG N.16952Associazione Italiana per la Ricerca sul Cancro IG N.20353Associazione Italiana per la Ricerca sul Cancro MYNERVA project, #21267AstraZeneca free research
6 · The paper itself

Abstract

Myelodysplastic syndromes (MDS) are highly heterogeneous myeloid diseases, characterized by frequent genetic/chromosomal aberrations. Olaparib is a potent, orally bioavailable poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with acceptable toxicity profile, designed as targeted therapy for DNA repair defective tumors. Here, we investigated olaparib activity in primary cultures of bone marrow mononuclear cells collected from patients with MDS (

Indexed as

AMLhematopoietic differentiationMDSolaparibPARP1PARP inhibitors

Identifiers

PMID31527467
PMCPMC6769925
OpenAlexW2973975455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.